Commentary: Early antiretroviral therapy for HIV infection in sub-Saharan Africa, a challenging new step.
Recent changes in guidelines (World Health Organization (WHO), USA, and likely Europe soon) all move towards earlier initiation of antiretroviral therapy in asymptomatic patients infected with human immunodeficiency virus (HIV). Sonia Menon appropriately questions the feasibility and consequences at both individual and community levels of the early initiation of antiretroviral therapy in sub-Saharan Africa as likely effects will be both positive and negative. Local context should drive the uptake process in every country. Money, national and international, will be essential for the successful implementation of the new WHO recommendation. Leaders at both levels must take their responsibilities and mobilize the necessary resources, for example, doubling those for the Global Fund to Fight AIDS, Tuberculosis and Malaria from $10 billion to $20 billion USD for 2011-2013.
Institut de Recherche pour le Développement (UMR 145), 911 avenue Agropolis, BP 64501, 34394 Montpellier, Cedex 5, France. Christian.Laurent@ird.fr
Christian
C
Laurent
D017954:Africa South of the Sahara / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D003906:Developing Countries; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D017410:Practice Guidelines as Topic; D013997:Time Factors; D014944:World Health Organization
D019380:Anti-HIV Agents